+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Retinal vein occlusions treated by intravitreal bevacizumab injections at the Hospital of Instruction, Application and Reference of the Armed Forces of Yaoundé



Retinal vein occlusions treated by intravitreal bevacizumab injections at the Hospital of Instruction, Application and Reference of the Armed Forces of Yaoundé



Journal Francais d'Ophtalmologie 2019:



To assess the anatomical and functional results of intravitreal bevacizumab injections in retinal vein occlusions at the Hospital of Instruction, Application and Reference of the Armed Forces of Yaoundé. A prospective and descriptive study was conducted from October 2016 to August 2017 at the Hospital of Instruction, Application and Reference of the Armed Forces of Yaoundé. All eyes with edematous or mixed retinal vein occlusion were treatment naive and received at least 3 intravitreal injections spaced at least 28 days apart of bevacizumab 25mg/ml at a dose of 0.05ml per session according to the strategy of 3 injections or "3 I". At least 3 months after the final injection, visual acuity and macular thickness, assessed by optical coherence tomography, were analyzed with the IBM-SPSS 22 software. The Student's test was used to compare means, with a significance P<5%. We included nineteen eyes of 18 patients with a mean age of 62.83±9.57 years. The male to female sex ratio was 0.8. Branch vein occlusion was predominant in 14 (73.68%) eyes. The edematous type was noted in 17 (89.5%) eyes. Serous retinal detachment was present in 6 (31.6%) eyes. The mean number of injections was 4.2±1.2. The mean baseline visual acuity changed from +0.9 Log MAR (40 ETDRS) to +0.6 Log MAR (55 ETDRS) at 6 months, while the mean macular thickness went from 550.16±180μm to 338.58±127μm, with statistically significant differences. Intravitreal bevacizumab injections proved to be effective in the management of edematous retinal vein occlusions in our practice setting despite the lack of market authorization for this indication.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 069614952

Download citation: RISBibTeXText

PMID: 31837895


Related references

Initial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary to branch retinal vein occlusion. Biomed Research International 2013: 209735, 2013

Intravitreal triamcinolone after intravitreal bevacizumab for retinal vein occlusions. Acta Ophthalmologica 88(2): E24, 2010

Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion. Acta Ophthalmologica 92(7): E530, 2014

Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology 250(8): 1149-1160, 2012

Intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion persisting despite multiple intravitreal bevacizumab injections. Journal of Ocular Pharmacology and Therapeutics 30(6): 512-516, 2014

Macular thickness might be a recurrence probability predictor in macular edema due to retinal vein occlusions treated with repeated intravitreal injections of antiangiogenics. Archivos de la Sociedad Espanola de Oftalmologia 84(4): 177-178, 2009

Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27(2): 141-149, 2007

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions. Clinical Ophthalmology 11: 1183-1190, 2017

Intravitreal triamcinolone acetonide injections in the treatment of retinal vein occlusions. Ophthalmic Surgery Lasers and Imaging 39(6): 446-454, 2008

Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. Journal of Ocular Pharmacology and Therapeutics 31(2): 78-86, 2015

Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ). Acta Ophthalmologica 88(8): 836-841, 2010

Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology 255(3): 457-462, 2017

Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology 255(5): 1045-1046, 2017

The short-term effects of intravitreal aflibercept injections and dexamethasone implant on ocular hemodynamics in retinal vein occlusions. Therapeutics and Clinical Risk Management Volume 15: 823-830, 2019

Effect of repeated intravitreal bevacizumab injections for secondary macular edema of branch retinal vein occlusion. Nippon Ganka Gakkai Zasshi 114(12): 1013-1018, 2010